HSY244
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 27, 2023
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation
(clinicaltrials.gov)
- P2 | N=13 | Terminated | Sponsor: Novartis Pharmaceuticals | N=29 ➔ 13 | Trial completion date: Jul 2025 ➔ Jul 2022 | Recruiting ➔ Terminated | Trial primary completion date: Jul 2025 ➔ Jul 2022; Terminated due to business decision
Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure
December 15, 2022
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation
(clinicaltrials.gov)
- P2 | N=29 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Nov 2022 ➔ Jul 2025 | Trial primary completion date: Nov 2022 ➔ Jul 2025
Trial completion date • Trial primary completion date • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure
October 28, 2021
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation
(clinicaltrials.gov)
- P2; N=40; Recruiting; Sponsor: Novartis Pharmaceuticals; Trial completion date: Apr 2022 ➔ Aug 2022; Trial primary completion date: Apr 2022 ➔ Aug 2022
Clinical • Trial completion date • Trial primary completion date • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure
January 25, 2021
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HSY244 in Participants With Atrial Fibrillation
(clinicaltrials.gov)
- P2; N=40; Recruiting; Sponsor: Novartis Pharmaceuticals; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Atrial Fibrillation • Cardiovascular
1 to 4
Of
4
Go to page
1